-
Product Insights
Retinoblastoma - Drugs In Development, 2024
Empower your strategies with our Retinoblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris, and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy, and surgery. The Retinoblastoma drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
Malignant Fibrous Histiocytoma of Soft Tissue - Drugs In Development, 2024
Empower your strategies with our Malignant Fibrous Histiocytoma of Soft Tissue – Drugs In Development, 2024 report and make more profitable business decisions. Malignant fibrous histiocytoma (MFH), now known as undifferentiated pleomorphic sarcoma, is a type of cancerous tumor that originates in the bone or soft tissue or other organ parts of the body. It is the most common form of soft tissue tumors generally seen in adults and very rarely in children. It is a painless mass believed to originate...
-
Product Insights
Pheochromocytoma - Drugs In Development, 2024
Empower your strategies with our Pheochromocytoma – Drugs In Development, 2024 report and make more profitable business decisions. Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops from cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath, and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL), and neurofibromatosis 1 (NF1). The Pheochromocytoma drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
Secondary CNS Lymphoma - Drugs In Development, 2024
Empower your strategies with our Secondary CNS Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Lymphoma in CNS (parts of the brain) is known as secondary CNS lymphoma (SCNSL). It is a form of CNS lymphoma where the risk of developing secondary lymphoma is 5-15%. It involves brain, eyes, spinal cord, meninges, as these are BBB (blood brain barriers) it creates a therapeutic challenge in managing this condition while relapse of the condition is also seen....
-
Product Insights
Wilms' Tumor (Nephroblastoma) - Drugs In Development, 2024
Empower your strategies with our Wilms' Tumor (Nephroblastoma) – Drugs In Development, 2024 report and make more profitable business decisions. Wilms' Tumor also known as Nephroblastoma is a type of cancer in one kidney commonly seen in children and is the most common cancer in children around 3-5 years of age and rarely observed in adults. Although the exact cause is idiopathic genetic alterations in WT1, CTNNB1, and WTX, TP53 and MYNC are believed to cause this. Tumor originates from the...
-
Product Insights
Bone Tumor - Drugs In Development, 2024
Empower your strategies with our Bone Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Bone Tumor or bone cancer affecting any bone in the body. Most of the bone cancers are benign while some are malignant or cancerous. This occurs when bone cells divide uncontrollably. Osteosarcoma, Ewing sarcoma, chondrosarcoma are the types of sarcomas. Most commonly occurs in children than in adults. Etiology is idiopathic. Pain in bones, swelling, fatigue, fever, weight loss are some common...
-
Product Insights
Ductal Carcinoma - Drugs In Development, 2024
Empower your strategies with our Ductal Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Ductal Carcinoma is early stage of breast cancer where the ductal cells of the breast tissue tend to multiply or grow uncontrollably without any evidence of metastatic. If not treated in initial stages, this could be invasive. Ductal carcinoma is represented in 4 different stages, pre invasive, non-invasive, ductal intraepithelial neoplasia, intra ductal cancer. In invasive form spread of cancer cells into...
-
Product Insights
Plasma Cell Neoplasm - Drugs In Development, 2024
Empower your strategies with our Plasma Cell Neoplasm – Drugs In Development, 2024 report and make more profitable business decisions. Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some...
-
Product Insights
Post-Transplant Lymphoproliferative Disorder - Drugs In Development, 2024
Empower your strategies with our Post-Transplant Lymphoproliferative Disorder – Drugs In Development, 2024 report and make more profitable business decisions. Post-Transplant Lymphoproliferative Disorder is a complication of organ transplantation and is a life-threatening condition. Infections occurring because of low immunity like EBV (Epstein-Barr virus) also known common cause. Symptoms are non-specific and varies from one another but most commonly fever, malaise, weight loss are seen. EBV tests, CBP, Urine analysis, CT-scan, PET scan are the common diagnostics methods. As Immunosuppressants are...
-
Product Insights
Tenosynovial Giant Cell Tumor - Drugs In Development, 2024
Empower your strategies with our Tenosynovial Giant Cell Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Tenosynovial Giant Cell Tumors are non-cancerous or benign form of tumors arising from the synovium of the joints or in the soft tissues. Genetically caused due to mutations in the stromal cells of synovium and is divided into three different types as Giant cell tumors of the synovium, Giant cell tumors of the tendon sheath, Giant cell tumors of the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.